Accelerated Approval Now Starting Point For Gene Therapy Development, US FDA’s Marks Says

Expedited approval pathway had been a secondary option when traditional approval was not possible, but the CBER director wants surrogate endpoints increasingly considered from the beginning, especially with pediatric rare disease gene therapies.

start
Going forward, accelerated approval will not be an afterthought for gene therapies, Peter Marks said. • Source: Shutterstock

Gene therapy sponsors now should expect accelerated approval to be on the table from the beginning of the development process, rather than as an alternative to a traditional pathway.

Peter Marks, director of the US Food and Drug Administration’s Center for Biologics Evaluation and Research, said the change in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies